JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.3
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 14, Issue 2 (2022)
Iran J War Public Health 2022, 14(2): 203-210 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2022/04/8 | Accepted: 2022/06/7 | Published: 2022/06/30
Received: 2022/04/8 | Accepted: 2022/06/7 | Published: 2022/06/30
How to cite this article
Abdul Jaleel A, Almulla A, Alnaji H, Mansor M, Abbas Abo Algon A. Diabetes Mellitus and Non-Proliferative Diabetic Retinopathy Are Accompanied by Increase Pro-Inflammatory Conditions Indicated by a High Blood-Derived Levels of Monocyte Chemoattractant Protein-1 and Interleukin-8. Iran J War Public Health 2022; 14 (2) :203-210
URL: http://ijwph.ir/article-1-1165-en.html
URL: http://ijwph.ir/article-1-1165-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq
2- Iraqi Education Ministry, Najaf, Iraq
2- Iraqi Education Ministry, Najaf, Iraq
Abstract (1195 Views)
Aims: Inflammatory conditions are probably implicated in the pathophysiology of diabetic retinopathy. This study aimed to investigate the levels of monocytes chemoattractant protein-1 and interleukin-8 in patients with diabetes mellitus and diabetic retinopathy and to indicate whether these chemokines can predict diabetic retinopathy or not.
Material & Methods: One-hindered fifty individuals were recruited in this study from Najaf city, Iraq. They were divided into three groups 50 diabetes mellitus diabetes mellitus patients, 50 non-proliferative diabetic retinopathy patients, and 50 healthy control. Enzyme-linked immunosorbent assays were used to assess monocytes chemoattractant protein-1 and interleukin-8 along with other spectrophotometric methods for determining other biomarkers.
Findings: The results indicate a significant difference (p<0.0001) in monocytes chemoattractant protein-1 and interleukin-8 between patients and healthy control and only monocytes chemoattractant protein-1 was a significant difference (p<0.0001) between diabetes mellitus and non-proliferative diabetic-retinopathy group. A correlation study revealed a significant positive correlation between chemokines and duration of illness (monocytes chemoattractant protein-1: rho=0.684, p<0.0001, interleukin-8; rho=0.704, p<0.0001). besides these chemokines also showed a significant direct correlation with HbA1c. Regression analysis showed a large effect size of these chemokines in predicting inflammatory conditions and diagnosis of diabetes mellitus. In addition, the level of monocytes chemoattractant protein-1 appears to predict patients with non-proliferative diabetic retinopathy.
Conclusion: Elevated levels of monocytes chemoattractant protein-1 and interleukin-8 in patients with diabetes mellitus suggest the implication of these chemokines in the pathophysiology of the disease and one of the contributors to developing complications such as diabetic retinopathy. Besides monocytes chemoattractant, protein-1 may predict the early stage of diabetic retinopathy.
Material & Methods: One-hindered fifty individuals were recruited in this study from Najaf city, Iraq. They were divided into three groups 50 diabetes mellitus diabetes mellitus patients, 50 non-proliferative diabetic retinopathy patients, and 50 healthy control. Enzyme-linked immunosorbent assays were used to assess monocytes chemoattractant protein-1 and interleukin-8 along with other spectrophotometric methods for determining other biomarkers.
Findings: The results indicate a significant difference (p<0.0001) in monocytes chemoattractant protein-1 and interleukin-8 between patients and healthy control and only monocytes chemoattractant protein-1 was a significant difference (p<0.0001) between diabetes mellitus and non-proliferative diabetic-retinopathy group. A correlation study revealed a significant positive correlation between chemokines and duration of illness (monocytes chemoattractant protein-1: rho=0.684, p<0.0001, interleukin-8; rho=0.704, p<0.0001). besides these chemokines also showed a significant direct correlation with HbA1c. Regression analysis showed a large effect size of these chemokines in predicting inflammatory conditions and diagnosis of diabetes mellitus. In addition, the level of monocytes chemoattractant protein-1 appears to predict patients with non-proliferative diabetic retinopathy.
Conclusion: Elevated levels of monocytes chemoattractant protein-1 and interleukin-8 in patients with diabetes mellitus suggest the implication of these chemokines in the pathophysiology of the disease and one of the contributors to developing complications such as diabetic retinopathy. Besides monocytes chemoattractant, protein-1 may predict the early stage of diabetic retinopathy.
Keywords:
References
1. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol. 2019;14(1):50-9. [Link] [DOI:10.15420/ecr.2018.33.1]
2. Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol. 2020;11:1582. [Link] [DOI:10.3389/fimmu.2020.01582]
3. Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021;325(18):1829-30. [Link] [DOI:10.1001/jama.2021.5469]
4. Menke A, Orchard TJ, Imperatore G, Bullard KM, Mayer-Davis E, Cowie CC. The prevalence of type 1 diabetes in the United States. Epidemiology. 2013;24(5):773-4. [Link] [DOI:10.1097/EDE.0b013e31829ef01a]
5. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54 Suppl 2: S97-107. [Link] [DOI:10.2337/diabetes.54.suppl_2.S97]
6. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-33. [Link] [DOI:10.2337/dc21-S002]
7. Baynest HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab. 2015;6(5). [Link] [DOI:10.4172/2155-6156.1000541]
8. Grossmann V, Schmitt VH, Zeller T, Panova-Noeva M, Schulz A, Laubert-Reh D, et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care. 2015;38(7):1356-64. [Link] [DOI:10.2337/dc14-3008]
9. Algon AAA, Almulla A, Najm AH, Keshwan RA. Role of glucagon-like peptide-1 in appetite regulation in patients with morbid obesity and leptin resistance. Int J Peptide Res Therapeutics. 2019;26(1):579-83. [Link] [DOI:10.1007/s10989-019-09864-w]
10. Donath MY. Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes. Endocrinology. 2011;152(11):4005-6. [Link] [DOI:10.1210/en.2011-1691]
11. Velloso LA, Eizirik DL, Cnop M. Type 2 diabetes mellitus--an autoimmune disease?. Nat Rev Endocrinol. 2013;9(12):750-5. [Link] [DOI:10.1038/nrendo.2013.131]
12. Itariu BK, Stulnig TM. Autoimmune aspects of type 2 diabetes mellitus - a mini-review. Gerontology. 2014;60(3):189-96. [Link] [DOI:10.1159/000356747]
13. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia. 1998;41(10):1241-8. [Link] [DOI:10.1007/s001250051058]
14. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. [Link] [DOI:10.1038/nri2925]
15. Luotola K, Pietilä A, Zeller T, Moilanen L, Kähönen M, Nieminen MS, et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. J Intern Med. 2011;269(3):322-32. [Link] [DOI:10.1111/j.1365-2796.2010.02294.x]
16. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-34. [Link] [DOI:10.1001/jama.286.3.327]
17. Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care. 2009;32(3):421-3. [Link] [DOI:10.2337/dc08-1161]
18. Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP, Gomes KB. The linkage between inflammation and Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2013;99(2):85-92. [Link] [DOI:10.1016/j.diabres.2012.09.003]
19. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813-23. [Link] [DOI:10.2337/diacare.27.3.813]
20. Tsegaw A, Alemu S, Dessie A, Patterson CC, Parry EHO, Phillips DIW, et al. Diabetic retinopathy in type 2 diabetes mellitus patients attending the diabetic clinic of the University of Gondar Hospital, Northwest Ethiopia. J Ophthalmol. 2021;2021:6696548. [Link] [DOI:10.1155/2021/6696548]
21. Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):1816. [Link] [DOI:10.3390/ijms19061816]
22. GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144-60. [Link]
23. Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580-91. [Link] [DOI:10.1016/j.ophtha.2021.04.027]
24. Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 1998;39(11):2190-4. [Link]
25. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol. 2011;55(3):256-63. [Link] [DOI:10.1007/s10384-011-0004-8]
26. Reddy S, Amutha A, Rajalakshmi R, Bhaskaran R, Monickaraj F, Rangasamy S, et al. Association of increased levels of MCP-1 and cathepsin-D in young onset type 2 diabetes patients (T2DM-Y) with severity of diabetic retinopathy. J Diabetes Complications. 2017;31(5):804-9. [Link] [DOI:10.1016/j.jdiacomp.2017.02.017]
27. Taghavi Y, Hassanshahi G, Kounis NG, Koniari I, Khorramdelazad H. Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations. J Cell Commun Signal. 2019;13(4):451-62. [Link] [DOI:10.1007/s12079-018-00500-8]
28. Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22(6):719-722. [Link] [DOI:10.1111/j.1464-5491.2005.01538.x]
29. Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vision. 2009;15:1906-14. [Link]
30. Mussa BM, Srivastava A, Al-Habshi A, Mohammed AK, Halwani R, Abusnana S. Inflammatory biomarkers levels in T2DM Emirati patients with diabetic neuropathy. Diabetes Metab Syndr Obes. 2021;14:3389-97. [Link] [DOI:10.2147/DMSO.S319863]
31. Panee J. Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes. Cytokine. 2012;60(1):1-12. [Link] [DOI:10.1016/j.cyto.2012.06.018]
32. Pan X, Kaminga AC, Wen SW, Liu A. Chemokines in prediabetes and type 2 diabetes: a meta-analysis. Front Immunol. 2021;12: 622438. [Link] [DOI:10.3389/fimmu.2021.622438]
33. Bruun JM, Lihn AS, Madan AK, Pedersen SB, Schiøtt KM, Fain JN, Richelsen B. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab. 2004;286(1):E8-13. [Link] [DOI:10.1152/ajpendo.00269.2003]
34. Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes. 2005;29(1):146-50. [Link] [DOI:10.1038/sj.ijo.0802839]
35. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003;100(12):7265-70. [Link] [DOI:10.1073/pnas.1133870100]
36. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes. 2006;30(9):1347-55. [Link] [DOI:10.1038/sj.ijo.0803259]
37. Borilova Linhartova P, Kavrikova D, Tomandlova M, Poskerova H, Rehka V, Dušek L, et al. Differences in interleukin-8 plasma levels between diabetic patients and healthy individuals independently on their periodontal status. Int J Mol Sci. 2018;19(10):3214. [Link] [DOI:10.3390/ijms19103214]
38. Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K, Hori S. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005;243(1):3-8. [Link] [DOI:10.1007/s00417-004-0950-7]
39. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20(12):1366-9. [Link] [DOI:10.1038/sj.eye.6702138]
40. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73-9. [Link] [DOI:10.1016/j.ophtha.2008.09.037]
41. Almulla AF, Vasupanrajit A, Tunvirachaisakul C, Al-Hakeim HK, Solmi M, Verkerk R, et al. The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum and plasma compartments. Mol Psychiatry. 2022 Apr. [Link] [DOI:10.1038/s41380-022-01552-4]